

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 30, 2023**

**Finch Therapeutics Group, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-40227**  
(Commission  
File Number)

**82-3433558**  
(IRS Employer  
Identification No.)

**75 State Street, Suite 100**  
**Boston, Massachusetts**  
(Address of Principal Executive Offices)

**02109**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (617) 229-6499**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                      | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|--|----------------------|--|
| Common Stock \$0.001 par value per share | FNCH                 | The Nasdaq Stock Market LLC                  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 1.02 Termination of a Material Definitive Agreement.**

As previously disclosed in its Current Report on Form 8-K filed on May 18, 2023, Finch Therapeutics, Inc., a subsidiary of Finch Therapeutics Group, Inc. (the “Company”), entered into a Lease Termination Agreement (the “Termination Agreement”) with NRL WCS 200 Inner Belt Prop, LLC (the “Landlord”) on May 12, 2023 related to the Company’s office lease agreement, dated as of December 21, 2015, between North River II LLC and NextBiome, Inc. (as subsequently amended and assigned to NRL WCS 200 Inner Belt Prop, LLC and Finch Therapeutics, Inc., respectively, the “Lease”), pursuant to which the Company leased approximately 10,500 square feet on the first floor and 25,785 square feet on the fourth floor of office and laboratory space at 200 Inner Belt Road, Somerville, Massachusetts (the “Premises”). In accordance with the terms of the Termination Agreement, the Landlord executed a new lease agreement with a third-party tenant for the Premises, and as a result, the Lease terminated on June 30, 2023. In connection with the termination, the Company’s rent obligations ended on June 30, 2023. Pursuant to the Termination Agreement, the Landlord agreed to refund the Company for the full amount of the Company’s security deposit.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**FINCH THERAPEUTICS GROUP, INC.**

Date: July 7, 2023

By: /s/ Matthew P. Blischak

Matthew P. Blischak

President and Chief Executive Officer